ETEST® Ceftazidime/ Avibactam

Improving Therapeutic Decisions

ETEST is a well-established method for antimicrobial susceptibility testing in microbiology laboratories around the world. ETEST consists of a predefined gradient of antibiotic concentrations on a plastic strip and is used to determine the Minimum Inhibitory Concentration (MIC) of antibiotics, antifungal agents and antimycobacterial agents. Learn more about ETEST

Now FDA 510(k) Cleared!

ETEST Ceftazidime/Avibactam
(CZA 0.016-256 µg/mL)

Order online!

Antimicrobial resistance: Why accurate susceptibility results can help enhance your Antimicrobial Stewardship Programs

Antimicrobial resistance is one of today’s top healthcare concerns worldwide. With the development of Multi-drug Resistant Organisms (MDRO), particularly Gram-negative bacteria, even infections that were once easy to treat can be life-threatening.1 Antimicrobial stewardship – appropriate selection and use of antimicrobials – helps improve patient outcomes, prevent resistance development and preserve the effectiveness of new antimicrobials, such as the ceftazidime/avibactam combination drug. In this context, it’s important for clinicians to have clear and reliable information to make the best decisions for antibiotic therapy – before, during and after treatment. A key part of this is accurate and rapid antimicrobial susceptibility testing – for ceftazidime/avibactam, there’s now ETEST Ceftazidime/Avibactam (0.016-256 µg/mL).

Exact MICs: Real precision in ETEST Ceftazidime/Avibactam (0.016-256 µg/mL)

Thanks to the determination of exact MIC values, ETEST Ceftazidime/Avibactam (0.016-256 µg/mL) strips offer greater precision than conventional two-fold dilutions (i.e., half dilutions) with interpretive category (S, I, R). In as little as 16 hours incubation, you can determine how susceptible the organism is, not just if it is susceptible. This information helps clinicians make informed patient-care decisions for ceftazidime/avibactam therapy and reduce the risk of development of drug-resistant bacteria. Epidemiological tracking of evolution of infectious organisms is also possible with MIC values, helping detect emergence of resistance over time.

ETEST: Easy, effective and precise

The new ETEST Ceftazidime/Avibactam (0.016-256 µg/mL) strips are the latest addition to the ETEST range – the original gradient strips – which are widely documented for their effectiveness and precision.

Comprised of a MIC reading scale and an antibiotic gradient, ETEST strips are processed in a similar manner to diffusion methods. They differ in that the antimicrobial concentration gradient is preformed, predefined and stable, and not dependent on diffusion. On an inoculated agar surface, the antibiotic gradient forms a stable, continuous and exponential gradient of antibiotic concentration. Bacteria grow under the strip, forming an ellipse on the scale, on which you can read the MIC value. More than 90 antimicrobial references are available in the ETEST range, for easy, effective and precise testing for antibiotics and antifungals, as well as for antimicrobial resistance detection (ARD).

ETEST Ceftazidime/Avibactam (0.016-256 µg/mL)

ETEST Ceftazidime/Avibactam (0.016-256 µg/mL) strips determine exact Minimum Inhibitory Concentration (MIC) values to assess susceptibility to ceftazidime/avibactam, a new antimicrobial developed to treat some serious infections for which few effective therapies exist.1,2,3 Ceftazidime/avibactam acts on Gram-negative bacteria and is indicated for complicated intra-abdominal infections (cIAI) in combination with metronidazole, as well as for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis (AP), in patients over 18.

Content of the Kit

REF 419046

Single Pack: 30 test strips

  • Ceftazidime MIC range: 0.016-256 µg/mL
  • Avibactam:  4 µg/mL

Ordering Contact Information

Customer Service: (800) 682-2666 

To order please visit:
www.biomerieuxDIRECT.com

ETEST Application Guide

For information about the many uses of ETEST, by organism, download the ETEST Application Guide here.

ETEST Technical Library

  • Please navigate to Technical Library at top left or at www.mybiomerieux.com (requires login).
  • To access ETEST related documents, select Guided Search by a reagent;
  • Click the “+” by ETEST; the desired ETEST product area, for example “Antimicrobial Susceptibility Testing”.
  • In the ensuing list of Available Products, select the product of interest.
  • The ETEST package insert is Package Insert US ‐ 15203 ‐ x ‐ en ‐ ETEST ‐ AST.pdf. Supplementary Inserts specific to each antimicrobial are also available.
  • For the ETEST Application Guide, select Guided Search by reagents; click the Search by product box, enter “410440 -ETEST Additional Technical Documents and Search Instructions”, then “Supplementary Inserts ‐ 16273 ‐ A ‐ en ‐ EAG ‐ ETEST Application Guide.pdf”.

For new users, please request a login; logins are returned during business hours.


References:

1. Mosley JF, Smith LL, Parke CK, Brown JA, Wilson AL, Gibbs LV. Ceftazidime-Avibactam (Avycaz) for the treatment of complicated intra-abdominal and urinary tract infections. PT. 2016;41(8):479-483.
2. Nicolau DP. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opin Investig Drugs. 2015;24(9):1261-1273.
3. Carmeli Y, Armstron J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661-673.
 
AVYCAZ® and its design are trademarks of Forest Laboratories, LLC, an Allergan affiliate

Downloads

 ETEST Catalog

 

 ETEST Price List

 

 Ceftazidime/Avibactam Postcard

ETEST Publications

1. Mosley JF, Smith LL, Parke CK, Brown JA, Wilson AL, Gibbs LV. Ceftazidime-Avibactam (Avycaz) for the treatment of complicated intra-abdominal and urinary tract infections. PT. 2016;41(8):479-483.

2. Nicolau DP. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opin Investig Drugs. 2015;24(9):1261-1273.

3. Carmeli Y, Armstron J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661-673.

Pioneering Diagnostics